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A Retinal Tear Induced By Pazopanib Therapy:
A Case Report
Raza Hasan, MD

Introduction
The management of renal cell carcinoma has undergone
major transformation in recent years. With the onset of
innovative surgical treatments and systemic medications
– there has been an overall decrease in mortality.1 The
systemic medications that target the vascular endothelial
growth factor (VEGF) protein have created the most
potent effects, especially when treating metastatic renal
cell carcinoma. These prove to be important treatments
since renal cell carcinoma has become the seventh
most common cancer in men, with a general prevalence
of 2-3%.2 With more advancement in knowledge about
renal cell carcinoma, research has shown the utility of
pazopanib (Votrient), a specific tyrosine kinase inhibitor,
targeting multiple receptors; its action is primarily to
block angiogenesis and tumor growth, such as VEGFR-1,
VEGFR-2, VEGFR-3, PDGFR-A, PDGFR-B, FGFR-1, and
FGFR-3. 3 Targeting these specific receptors helps
pazopanib to achieve an overall clinical benefit rate of
greater than 90%, creating long-lasting disease control
for patients 4

Additional therapeutic options were discussed with
the patient, such as high-dose interleukin-2 infusion
to achieve durable remission and then potentially start
targeted therapy when needed. At the time when she
was diagnosed with metastatic disease, the patient
was in optimal health and was an excellent candidate
for high-dose interleukin-2 treatment because she only
had pulmonary nodules, without evidence of metastatic
disease elsewhere in her body. She was agreeable and
finished three cycles of high-dose interleukin-2 treatment
along with Stereotactic Body Radiation Therapy. The
patient was finally started on targeted therapy with a
multi-tyrosine kinase inhibitor in June of 2013. Pazopanib
400mg daily was started and titrated up to 600mg
daily, which is considered optimal therapy. However,
this patient began to have significant diarrhea without
relief from Lomotil and other antidiarrheal medication
regimens. Her dose was decreased to 400mg daily
which resulted in a decreased amount of diarrhea - one
to two times a day which was tolerable. Additionally, a
few months after the onset of pazopanib treatment, the
patient began having blurry vision, a symptom which
was very worrisome.

CASE PRESENTATION
A 63 year old Caucasian female with a past medical
history of migraine headaches, dyslipidemia and
depression was diagnosed with clear cell type Renal
Cell Cancer, in late 2004. She underwent a laparoscopic
nephrectomy in 2005 and a kidney mass measuring 9 x
7 x 4 cm was removed, revealing T2 disease with Furman
Grade 2 disease. The patient was followed for years and
had a CT scan of her Chest in June of 2012 - where
multiple bilateral pulmonary nodules were identified, the
largest nodule was a 1.5 x 1.2 cm nodule at the right
middle lobe. CT-guided biopsy was attempted, however
was not diagnostic. Therefore, the patient underwent a
right upper lobe wedge resection in October of 2012,
which confirmed metastatic renal cell cancer to the
lung. A PET/CT scan was also performed, and ruled out
any evidence of abdominal or bone metastatic disease.
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DIFFERENTIAL DIAGNOSIS
The patient’s blurry vision was the main symptom of
concern – her vision had been gradually worsening
since the start of pazopanib therapy. Therefore, it was
suspected that the systemic therapy was a plausible
causal agent of the blurry vision. Upon visiting the ophthalmologist, she was diagnosed with Rhegmatogenous
Retinal Tear OD. Her past ocular history was negative
for any prior chronic diseases. On exam, the patient had
retinal detachment, superotemporal (horseshoe) tear.
Furthermore, the patient's left eye exam was remarkable
for nuclear sclerosis. It was likely determined that the
pazopanib caused a tear in the retina, thus further
leading to detachment
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OUTCOME AND FOLLOW-UP
To treat the pazopanib induced retinopathy, the patient
had a pneumatic retinopexy performed on August
19, 2014 and was started on Maxitrol 0.1% 1 drop OD,
four times a day. Post operatively, she had decreased
complaints of blurry vision. However, because of this
adverse event along with intractable diarrhea, the
patient was switched from pazopanib to Sutent 37.5mg
daily. The Patient is currently doing well – the blurry
vision has not worsened and is slowly improving after
stopping pazopanib.

DISCUSSION
The usage of pazopanib is a common treatment in
metastatic renal cell carcinoma. A multitude of studies
have shown that “pazopanib demonstrated significant
improvements in progression-free survival and response
rate compared with placebo in patients with advanced
or metastatic RCC.”7 Furthermore during these studies,
there were no reports of patients developing other
systemic abnormalities; the medication demonstrated
acceptable safety and tolerability. However, as
pazopanib is an oral angiogenesis inhibitor targeting
specifically VEGF receptor, it is important to evaluate
other locations in the body that might be affected
secondary to inhibiting VEGF receptors.
A recent study was published evaluating the ocular
effects of Sorafenib – as it was shown that many cancer
signaling molecules, such as VEGF, were also expressed
in ocular tissue.5,6 Sorafenib and Pazopanib have similar
pathways, both specifically targeting VEGF proteins and
thus both affecting the ocular tissue. Furthermore, there
have been studies analyzing the effect of pazopanib in
mice retinal tissues – specifically studying pazopanib’s
effect on inhibiting choroidal neovascularization. It was
shown that pazopanib primarily down-regulates the
VEGF release in the retina and impairs VEGF-induced
signaling and chemotaxis.8 Thus, a clear link is illustrated
between pazopanib and its effect on retinal tissue.
Furthermore, studies have shown that if pazopanib is
“orally administered, [it] has good bioavailability to the
retina/choroid” further giving proof to its profound
effect on the retina and likely impact on treating ocular
abnormalities, such as choroidal neovascularization by
inhibiting angiogenesis.9,10
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However, analysis of the link between pazopanib and
retinal tears is important to be determined – in order
to understand the findings in this case. Case reports of
retinal effects from Sorafenib have been reported, likely
secondary to a similarity between the VEGF receptors
targeted in systemic RCC and in ocular tissue; similarly
a comparison can be drawn between pazopanib and
its effects on ocular tissues. With pazopanib’s large
bioavailability in ocular tissues, and its direct effect on
VEGF receptors – there can be a correlation made
between pazopanib and retinal tears developing after
initiating chemotherapy. Retinal tears occur when
the retinal tissue begins to peel away from supporting
tissue. Rhegmatogenous retinal detachment, the type
of retinal attachment the patient in above case had,
occurs primarily when a small retinal tear allows for fluid
to pass from vitreous space into subretinal space where
the retinal pigment epithelium (RPE) is located. Studies
have illustrated that these tears are often preceded
by anti-VEGF therapy, stating that an “increased risk
of developing a retinal pigment epithelium tear after
anti-VEGF therapy” is common in many patients.11 This
occurs because following the administration of anti-VEGF
therapy, there is rapid involution and contraction of the
neovascular tissue that is attached to the undersurface of
the retinal pigment epithelium. Those forces will cause a
contractile force of the RPE forcing a tear on the retinal
tissue.12 Given the pathophysiology of retinal tears and
its relationship with anti-VEGF therapy – it is highly
probable that the repeated administration of pazopanib
in therapeutic doses for RCC can lead to strain of the
retinal pigment epithelium, inducing a tear and further
progressing onto a rhegmatogenous retinal detachment.

KEY POINTS
This case illustrates a risk with using VEGF inhibitors,
such as pazopanib, due to the possibility of retinal
damage causing tears leading to detachment. As in our
case, there is an increased amount of anti-VEGF being
used in renal cell carcinoma cases at therapeutic doses.
With the increased usage, guidelines may be required
for annual ophthalmology screening to monitor for
retinal abnormalities. Furthermore, follow up will be
required to determine if discontinuing the pazopanib
and starting Sutent helped deter further ocular
abnormalities. Overall, it should be recommended to
discontinue pazopanib if any blurry vision or vision
changes are noted.
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